Search | Clinical Trials Finder

Conditions: Healthy
Interventions: Relugolix, E2/NETA; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Endometriosis
Interventions: Relugolix, Estradiol/norethindrone acetate; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 60
States / cities: Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more

Conditions: Uterine Leiomyoma, Uterine Fibroids
Interventions: Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 72
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more

Conditions: Uterine Fibroids, Heavy Menstrual Bleeding
Interventions: OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 23
States / cities: Chino, California • Huntington Park, California • San Diego, California + 19 more

Conditions: Heavy Menstrual Bleeding, Uterine Fibroid
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 76
States / cities: Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more

Conditions: Heavy Menstrual Bleeding, Uterine Fibroids
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Endometriosis
Interventions: elagolix, estradiol/norethindrone acetate (E2/NETA); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 37
States / cities: Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more

Conditions: Endometriosis
Interventions: 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule; Drug
Lead sponsor: Kissei Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • Chiefland, Florida + 19 more

Conditions: Uterine Fibroids, Heavy Menstrual Bleeding
Interventions: Estradiol/Norethindrone Acetate, Elagolix; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 121
States / cities: Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 90 more

Conditions: Heavy Menstrual Bleeding, Uterine Fibroids
Interventions: Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 155
States / cities: Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more

Conditions: Healthy
Interventions: Relugolix/E2/NETA FDC, Relugolix, Erythromycin; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Heavy Menstrual Bleeding, Uterine Fibroid
Interventions: Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 89
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more

Conditions: Endometriosis
Interventions: 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule; Drug
Lead sponsor: Kissei Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 107
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more

Conditions: Postmenopause
Interventions: 0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella); Drug
Lead sponsor: Bayer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 662 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Chandler, Arizona • San Diego, California • Denver, Colorado + 13 more

Conditions: Uterine Fibroids, Heavy Menstrual Bleeding
Interventions: Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 103
States / cities: Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more

Conditions: Endometriosis
Interventions: Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 188
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more

Conditions: Contraception
Interventions: Relugolix Combination Therapy; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 109
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more

Conditions: Uterine Fibroids, Heavy Menstrual Bleeding
Interventions: Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 92
States / cities: Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 79 more

Conditions: Endometriosis
Interventions: 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule; Drug
Lead sponsor: Kissei Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 23
States / cities: Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more

Conditions: Endometriosis Related Pain
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 43
States / cities: Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more

Conditions: Endometriosis Related Pain
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 41
States / cities: Andalusia, Alabama • Washington D.C., District of Columbia • Aventura, Florida + 36 more

Conditions: Uterine Fibroids, Endometriosis
Interventions: Relugolix Combination Tablet; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 120
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more

Conditions: Endometriosis
Interventions: 75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo capsule to match Add-back capsule; Drug
Lead sponsor: Kissei Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Dothan, Alabama • Homestead, Florida • Tampa, Florida + 5 more

Conditions: Heavy Menstrual Bleeding, Uterine Fibroid
Interventions: Relugolix, Estradiol/norethindrone acetate; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 104
States / cities: Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more

Search by objective public record fields.

Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

Endometrial Safety Study

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids